Patent Analysis of Key Tech Domains & Status of Unidentified Stock 03628.HK

After multiple searches, no information was found for the stock code

(仁恒实业控股). This may indicate the stock is either non-existent or has been delisted.

The patent analysis covers multiple technology domains, with

accounting for the largest share (45%), followed by materials science (15%) and energy technology (12%).

1. CRISPR-CAS13 System
   : A gene editing technology with applications in genetic disease treatment.
2. 颅骨重建柔性铰链板
   : A medical device for craniotomy to reduce complications.
3. Cold Atmospheric Plasma Generator
   : Used in regenerative medicine and wound healing.
4. VR/AR System
   : Immersive technology based on user vision and head movement data.
5. Nuclear Power Plant Filter
   : Enhances safety and reliability of nuclear facilities.

• Academic Institutions
  : Zhejiang University, Tsinghua University, Chinese Academy of Sciences.
• Pharma Companies
  : ACERAND Therapeutics (gene editing), TEIJIN Pharma (medical devices).
• Tech Giants
  : Huawei (communication), Samsung (semiconductor), Siemens (industrial automation).

1. Gene Editing & Precision Medicine
   : Rapid advances in CRISPR technologies.
2. Smart Medical Devices
   : Minimally invasive and intelligent tools.
3. New Energy
   : Innovations in solar and energy storage systems.
4. VR/AR
   : Immersive experiences for education and entertainment.
5. Advanced Materials
   : Graphene and composites for aerospace and automotive sectors.

The patent landscape shows active innovation across multiple tech domains, with medical health leading. However, the stock 03628.HK remains unidentified, requiring further verification.